FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment

Approval Date:
The FDA approved the first generic version of Victoza (liraglutide injection) on December 23, 202413.

Treatment Use:
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in patients 10 years and older with Type 2 diabetes, alongside diet and exercise13.

Affordability:
Generic drugs like liraglutide provide additional treatment options that are generally more affordable for patients, expanding access to safe, effective, and high-quality generic drug products13.

Shortage Prevention:
The approval aims to help prevent shortages of GLP-1 receptor agonists, which have been in high demand for both diabetes and weight loss treatments13.

Novo Nordisk's Petition:
Novo Nordisk has petitioned the FDA to block compounded versions of Victoza, arguing there is no clinical need for such compounding5.

Generic Availability:
The generic version of Victoza is expected to be launched immediately by Hikma Pharmaceuticals, providing healthcare professionals and patients with an affordable and reliable supply of this essential medication3.

Sources:

1. https://www.drugs.com/news/fda-approves-glp-1-medicine-liraglutide-victoza-diabetes-123027.html

3. https://www.singlecare.com/blog/news/victoza-generic-approval/

5. https://www.pharmalive.com/novo-launches-citizen-petition-to-block-compounded-victoza/